NGNE
Neoleukin Therapeutics Inc (NGNE)
Healthcare • NASDAQ • $38.63+1.68%
- Symbol
- NGNE
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $38.63
- Daily Change
- +1.68%
- Market Cap
- $723.21M
- Trailing P/E
- N/A
- Forward P/E
- -6.98
- 52W High
- $43.66
- 52W Low
- $15.93
- Analyst Target
- $80.43
- Dividend Yield
- N/A
- Beta
- 1.95
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Company websiteResearch NGNE on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.